J. Loke

发表

Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature

Salam A. Assi, D. Westhead, Jason Piper, 2015, Cell reports.

Subtype-specific regulatory network rewiring in acute myeloid leukemia

Salam A. Assi, P. Cauchy, L. N. Gilding, 2018, Nature Genetics.

J. Loke, 2008, BMJ.

stem cell transplantation in patients with acute myeloid leukemia (AML) Azacitidine augments expansion of regulatory T cells after allogeneic

P. Vyas, C. Craddock, P. Moss, 2012 .

Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia

C. Craddock, K. Wheatley, J. Loke, 2014, Annals of Hematology.

MYELOID NEOPLASIA Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target

P. Kearns, P. Cheng, A. Beggs, 2015 .

Non‐pharmacological supportive‐care interventions in acute myeloid leukaemia: a review of randomised controlled trials

S. Stanworth, G. Prue, J. Loke, 2021, British journal of haematology.

Supportive care in the management of patients with acute myeloid leukaemia: where are the research needs?

S. Stanworth, D. Lowe, J. Loke, 2020, British journal of haematology.

University of Birmingham Subtype-specific regulatory network rewiring in acute myeloid leukemia

Salam A. Assi, L. N. Gilding, C. Bonifer, 2018 .

of The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia

C. Craddock, P. Moss, R. Malladi, 2019 .

Unravelling the apoptotic machinery in CMML.

P. Cockerill, J. Loke, 2021, Blood.

Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia

P. Ferguson, P. Hazlewood, S. Akiki, 2015, Leukemia.

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia

J. Esteve, N. Kröger, C. Craddock, 2022, Cancer.

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?

Richard J. Buka, C. Craddock, R. Buka, 2021, Frontiers in Immunology.

Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

C. Craddock, J. Loke, H. Vyas, 2021, Frontiers in Oncology.

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

P. Vyas, C. Craddock, S. Siddique, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience

C. Craddock, P. Moss, R. Malladi, 2019, British journal of haematology.

"Priority delivery" options for gene therapy.

J. Loke, 2021, Blood.

University of Birmingham Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia

J. Shabanowitz, D. Hunt, M. Cobbold, 2017 .

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.

P. Kearns, P. Cheng, A. Beggs, 2015, Blood.

Identification of common and distinct epigenetic re-programming properties of Core-Binding Factor (CBF) Fusion Proteins

P. Cauchy, C. Bonifer, P. Cockerill, 2016 .

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).

P. Vyas, C. Craddock, P. Moss, 2012, Blood.

Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT

A. Ganser, C. Craddock, M. Labopin, 2020, Bone Marrow Transplantation.

Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service

C. Craddock, C. Crawley, M. Dennis, 2021, Blood.

C/EBPα overrides epigenetic reprogramming by oncogenic transcription factors in acute myeloid leukemia.

Salam A. Assi, C. Bonifer, P. Cockerill, 2018, Blood advances.

FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research—a systematic review and meta-analysis

K. Wheatley, J. Loke, J. Wilson, 2020, Systematic Reviews.

Outcomes of EAM conditioned autologous haematopoietic SCT for lymphoma. A matched pairs retrospective single-centre study analysis

J. Ward, R. Malladi, P. Mahendra, 2013, Bone Marrow Transplantation.

Donor and recipient CMV serostatus and antigenemia after renal transplantation: An analysis of 486 patients

P. Klenerman, K. Welsh, P. Friend, 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Subtype-specific regulatory network rewiring in acute myeloid leukemia

Salam A. Assi, P. Cauchy, L. N. Gilding, 2018, Nature Genetics.

RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML

Salam A. Assi, P. Cauchy, C. Bonifer, 2017, Cell reports.

RUNX 1-ETO and RUNX 1E VI 1 Differentially Reprogram the Chromatin Landscape in t ( 8 ; 21 ) and t ( 3 ; 21 ) AML Graphical

P. Cauchy, C. Bonifer, P. Cockerill, 2022 .

Subtype-specific regulatory network rewiring in acute myeloid 1 leukemia 2

Salam A. Assi, L. N. Gilding, C. Bonifer, 2018 .

Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS

C. Craddock, S. Siddique, E. Tholouli, 2023, Blood advances.

Donor and recipient CMV serostatus and antigenemia after renal transplantation: An analysis of 486 patients

P. Klenerman, K. Welsh, P. Friend, 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.